Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Salesforce

Honeywell

An after-hours earnings beat lifted one of the soon-to-be Dow components even further.

Stock Markets Close Mixed, But the Dow's New Stocks Look Good

THOUSAND OAKS, Calif., Aug. 25, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of 12 cardiovascular scientific research abstracts, including clinical trial and real-world evidence studies of Repatha® (evolocumab), that add to the growing body of evidence.

New Amgen Data To Be Presented At ESC Congress 2020 Highlighting Repatha® (evolocumab) Efficacy In High-Risk Patient Populations

The company is set to become the first biotech included in the Dow Jones Industrial Average.

Why Amgen Stock Vaulted Higher Today

The venerable Dow Jones Industrial Average is being reshaped in significant fashion.

3 ETFs For The New Look Dow Jones Industrial Average

Pfizer

Raytheon

Exxon Mobil

Shares of the three new additions to the Dow Jones Industrial Average DJIA, +1.35% were higher in premarket trade Tuesday, while the three departing members moved lower, a day after S&P Dow Jones Indices announced a shake-up for the 30-member index.

Salesforce, Amgen and Honeywell higher premarket on Dow-joining news; Exxon, Pfizer and Raytheon move lower

The S&P Dow Jones Indices, a division of S&P Global (NYSE: SPGI), on Monday announced certain changes to the Dow Jones Industrial Average (DJIA) composition, effective Aug.

Apple Stock Split Causes Dow Jones Industrial Average Shuffle; Salesforce, Amgen, Honeywell To Make Entry

Amgen and Honeywell International are also graduating to the hallowed ranks of the Dow.

Salesforce to Join Dow Jones Industrial Average

The Dow Jones Industrial Average is getting a massive shakeup to balance out the disruption from Apple's stock split.

Major shakeup for the Dow Jones Industrial Average index: 3 new stocks join

NEW YORK, Aug. 24, 2020 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the Dow Jones Industrial Average (DJIA) effective prior to the opening of trading on Monday, August 31: Salesforce.com (NYSE:CRM) will replace Exxon Mobil Corp.

Salesforce.com, Amgen and Honeywell International Set to Join Dow Jones Industrial Average

Amgen, Salesforce.com and Honeywell will join the Dow Jones Industrial Average in a shuffling of the index that will give it more of a technology flavor.
The post Amgen, Salesforce.com, Honeywell Added To Dow Jones Industrial Average appeared first on Investor's Business Daily.

Amgen, Salesforce.com, Honeywell Added To Dow Jones Industrial Average

Shares of Salesforce.com , Amgen and Honeywell International each surged over 3% in extended trade on Monday after it was announced they would join the Dow Jones Industrial Average as of Aug. 31.

Salesforce, Amgen, Honeywell to join Dow Jones Industrial

The Dow Jones Industrial Average will lose its longest-standing component as part of the blue-chip index's biggest shakeup in years.

The Dow Announces Its Biggest Shakeup Since 2013

Salesforce.com Inc., Amgen Inc., and Honeywell International Inc. will become new members of the Dow Jones Industrial Average by the end of the month

Salesforce, Amgen, Honeywell to become new Dow Average components

Major changes are coming to the Dow Jones Industrial Average.

Salesforce, Amgen and Honeywell added to Dow in major shake-up to the average

AMGN's executive compensation plan lowers the risk of investing in the company’s stock because executives’ interests are tied to shareholders’ interests.

A Quality Exec Comp Plan Lowers The Risk Of Investing In Amgen Inc.

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Captisol customer Amgen (NASDAQ: AMGN) has received U.S. Food and Drug Administration (FDA) approval for the expansion of the KYPROLIS® (carfilzomib) U.S.

Ligand Announces Amgen’s KYPROLIS® Approved by FDA as Combination Regimen with DARZALEX® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma

LONDON--(BUSINESS WIRE)-- #GenericDrugsMarket--The Global Generic Drugs Market will grow by $ 123.50 mn during 2020-2024

Analysis on the Impact of COVID-19- Generic Drugs Market 2020-2024 | Evolving Opportunities With Amgen Inc. and Dr. Reddys Laboratories Ltd.

Amgen's (AMGN) Kyprolis gets FDA approval for label expansion as second to fourth-line treatment for relapsed/refractory multiple myeloma in combination with J&J's Darzalex and dexamethasone.

Amgen's New Kyprolis Combo Gets FDA Nod for Multiple Myeloma

Amgen stock broke out amid a two-pronged approach to coronavirus treatment, partnering with Adaptive Biotechnologies and testing Otezla in Covid-19. So, is Amgen stock a buy now?

Is Amgen Stock A Buy As It Takes A Dual Approach To Targeting Coronavirus?

THOUSAND OAKS, Calif., Aug. 20, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S.

FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens

Amgen produces relatively few drugs, but that doesn't mean it's any less essential or profitable.

How Amgen Makes Billions On Just A Few Drugs

The stock price of pharmaceutical giant Amgen has seen a growth of roughly 50% since the end of 2017, while its revenue grew a mere 3%. Large stock movements without any top line evidence are common in the pharmaceutical industry when promising drugs pass critical clinical trials or get approved.

Amgen Stock Up 50% But Revenues Grew Just 3%

THOUSAND OAKS, Calif., Aug. 13, 2020 /PRNewswire/ -- Amgen Inc.

Amgen Announces Pricing Terms For Senior Notes Exchange Offers, Increases The Maximum Notes Exchange Cap And Accepts Tendered Notes

Gilead Sciences

Moderna

The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.

US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch

Dynavax Technologies

Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.

News for Amgen Stock (AMGN)